

Second Announcement and Call for Posters




Image created by Louise Birch

29th Symposium on Medicinal Chemistry in Eastern England

Thursday 26th April 2018

Fielder Centre,
Hatfield, Hertfordshire, UK



ROYAL SOCIETY
OF CHEMISTRY

BIOLOGICAL AND
MEDICINAL
CHEMISTRY
SECTOR

Organised by RSC-BMCS (Royal Society of Chemistry - Biological and Medicinal Chemistry Sector)

Synopsis

The Symposium on Medicinal Chemistry in Eastern England, known colloquially as the "Hatfield MedChem" meeting, is a highly successful, long-standing, one-day meeting which runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics from the forefront of drug discovery of relevance to medicinal chemists. The meeting aims to be informal and interactive and the event will offer excellent scientific and networking opportunities for all those working in medicinal chemistry and drug discovery.

Call for Posters

Abstract submissions are invited for poster presentation. Please load an abstract template from the event website and return it the secretariat, by 23rd

Programme

- 09.00 Registration, refreshments and exhibition
- 09.30 Welcome and introduction
- 09.35 *Discovery of Padsevonil for the treatment of drug-resistant epilepsy* - Laurent Provins, UCB, Belgium
- 10.10 *Development of potent and selective ATM inhibitors for proof of concept studies in Huntington's disease* - Perla Breccia, Charles River Discovery, UK
- 10.45 *Discovery and characterisation of novel indoleamine 2,3-dioxygenase inhibitors* - Dean Boyall, Vertex Pharmaceuticals, UK
- 11.05 Refreshments and exhibition
- 11.35 *The development of hypoxia activated pro-drugs of the clinically approved KDAC inhibitor Panobinostat* - Stuart Conway, University of Oxford, UK
- 12.10 *A case study from DNA-encoded library screening* - Tom Miller, Shire, UK
- 12.45 Lunch and exhibition
- 13:50 Capps Green Zomaya Award presentation lecture
Discovery of GDC-0853: a highly potent, selective, and non-covalent Btk inhibitor
James Crawford, Genentech, USA
- 14.30 *From pan-kinase promiscuity to selective protein degradation using PROTACs* - Christopher Tinworth, GlaxoSmithKline, UK
- 14.50 *Scaling de novo design, from single target to disease portfolio* - Willem van Hoorn, ExScientia, UK
- 15.10 Refreshments and exhibition
- 15.40 Presentation title and speaker to be confirmed
- 16.00 *Non-cleavable pyrrolobenzodiazepine antibody-drug conjugates* - Stephen J Gregson, Spirogen, UK
- 16.20 *ASTX660, the first fragment-derived IAP antagonist in the clinic* - Ben Cons, Astex Pharmaceuticals, UK
- 16.55 Concluding remarks and close (at 17.00)


Registration

Registration is open - see website for details.

Secretariat Contact

Maggi Churchouse Events
Telephone: +44 (0)1359 221004
maggi@maggichurchousevents.co.uk

Website: www.maggichurchousevents.co.uk/BMCS (also www.rsc.org/bmcs)



Sponsors

Sponsors are encouraged to support this popular event.

Organising Committee

Seb Campos, GlaxoSmithKline
Adrian Hall, UCB
Nicole Hamblin, Charles River (chair)